MarketLens
Sign Up

Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future

4 months ago
SHARE THIS ON:

Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 week ago

GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments

GSK is advancing long-acting and combination respiratory medicines, with a focus on COPD, a senior research executive said at Guggenheim's Healthcare Innovation Conference. No timelines or financial f...
Stock News•1 months ago

Summit Shares Jump on $2B Strategic Investment From AstraZeneca

Summit Therapeutics shares jumped after AstraZeneca committed $2B to accelerate ivonescimab development and expand clinical collaboration.
Stock News•4 months ago

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma

Zymeworks acquired Theravance Biopharma for $929M, gaining Yupelri's ~$60M annual cash flows with patent protection to 2039, diversifying beyond oncology and reducing equity reliance.

Breaking News

View All →

Top Headlines

View More →
Stock News•30 minutes ago

Madison Huang, Jensen Huang's Daughter, Became a Powerful Force at Nvidia

Stock News•45 minutes ago

Tech Leaders Want Jensen Huang to Return to Nvidia. Here's What That Would Mean for the Stock Price.

Stock News•1 hour ago

Stock Market Today, Nov. 16: Nvidia Sinks as U.S. Tightens AI Chip Restrictions and Analysts Slash Price Targets

Stock News•1 hour ago

Why Nvidia Stock Fell Again

Stock News•1 hour ago

Stock Market Today, Nov. 16: Amazon Falls on New AI Chip Export Rule and Leo Satellite Launch Failure